- Home
- NXGL vs TNXP Comparison
NXGL vs TNXP Comparison
Compare NXGL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- TNXP
- Stock Information
- Founded
- NXGL 1997
- TNXP 2007
- Country
- NXGL United States
- TNXP United States
- Employees
- NXGL N/A
- TNXP N/A
- Industry
- NXGL Medical/Dental Instruments
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- TNXP Health Care
- Exchange
- NXGL Nasdaq
- TNXP Nasdaq
- Market Cap
- NXGL 22.7M
- TNXP 19.5M
- IPO Year
- NXGL 2021
- TNXP N/A
- Fundamental
- Price
- NXGL $4.73
- TNXP $0.61
- Analyst Decision
- NXGL
- TNXP Strong Buy
- Analyst Count
- NXGL 0
- TNXP 2
- Target Price
- NXGL N/A
- TNXP $53.50
- AVG Volume (30 Days)
- NXGL 168.1K
- TNXP 202.6M
- Earning Date
- NXGL 11-13-2024
- TNXP 11-12-2024
- Dividend Yield
- NXGL N/A
- TNXP N/A
- EPS Growth
- NXGL N/A
- TNXP N/A
- EPS
- NXGL N/A
- TNXP N/A
- Revenue
- NXGL $6,729,000.00
- TNXP $11,291,000.00
- Revenue This Year
- NXGL $120.47
- TNXP $64.71
- Revenue Next Year
- NXGL $38.19
- TNXP $24.49
- P/E Ratio
- NXGL N/A
- TNXP N/A
- Revenue Growth
- NXGL 90.57
- TNXP 183.05
- 52 Week Low
- NXGL $1.84
- TNXP $0.12
- 52 Week High
- NXGL $5.10
- TNXP $14.08
- Technical
- Relative Strength Index (RSI)
- NXGL 66.45
- TNXP 75.02
- Support Level
- NXGL $4.11
- TNXP $0.32
- Resistance Level
- NXGL $5.10
- TNXP $0.72
- Average True Range (ATR)
- NXGL 0.40
- TNXP 0.15
- MACD
- NXGL 0.08
- TNXP 0.04
- Stochastic Oscillator
- NXGL 78.98
- TNXP 39.61
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.